Cargando…

CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials

BACKGROUND: Updated evidence was required to compare the efficacy and safety of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) inhibitors for patients with hormone receptor-positive and HER2-ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hangcheng, Wang, Yan, Han, Yiqun, Wu, Yun, Wang, Jiayu, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449843/ https://www.ncbi.nlm.nih.gov/pubmed/36091147 http://dx.doi.org/10.3389/fonc.2022.956464

Ejemplares similares

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
por: Ji, Danyang, et al.
Publicado: (2023)

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
por: Han, Yiqun, et al.
Publicado: (2022)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis
por: Wang, Yan, et al.
Publicado: (2022)

Engineering prodrug nanomicelles as pyroptosis inducer for codelivery of PI3K/mTOR and CDK inhibitors to enhance antitumor immunity
por: Yang, Qichao, et al.
Publicado: (2022)

Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
por: Roudsari, Nazanin Momeni, et al.
Publicado: (2021)

Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy
por: Ghareghomi, Somayyeh, et al.
Publicado: (2023)

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population‐based analysis
por: Xu, Hangcheng, et al.
Publicado: (2022)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
por: Wu, Xianbo, et al.
Publicado: (2022)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
por: Presti, Daniele, et al.
Publicado: (2019)

Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer
por: Weng, Min, et al.
Publicado: (2022)

Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2020)

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models
por: Rodriguez, María Jimena, et al.
Publicado: (2023)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Differential Effects of Selective Inhibitors Targeting the PI3K/AKT/mTOR Pathway in Acute Lymphoblastic Leukemia
por: Badura, Susanne, et al.
Publicado: (2013)

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors
por: Philip, Charles-André, et al.
Publicado: (2017)

Virtual docking screening and QSAR studies to explore AKT and mTOR inhibitors acting on PI3K in cancers
por: Kandoussi, Ilham, et al.
Publicado: (2020)

Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
por: Chen, Dongshao, et al.
Publicado: (2018)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011)

Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells
por: Wang, Jian, et al.
Publicado: (2021)

A Mechanism for Synergy with Combined mTOR and PI3 Kinase Inhibitors
por: Yang, Shujie, et al.
Publicado: (2011)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer
por: Luo, Leixuan, et al.
Publicado: (2023)

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
por: Moore, Nathan F., et al.
Publicado: (2014)

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
por: Nepstad, Ina, et al.
Publicado: (2019)

Combination Effect of Notch1 and PI3K/AKT/mTOR Signaling Pathways Inhibitors on T-ALL Cell Lines
por: Khoshamooz, Halimeh, et al.
Publicado: (2020)

Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma
por: Uva, Paolo, et al.
Publicado: (2021)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
por: Fujimoto, Yumi, et al.
Publicado: (2020)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hb7pn32cf3f7s1dl0bb2u968h2